Immune training MS trial 'safe'

Nerves Myelin insulates nerves

Related Stories

An experimental treatment to stop the body attacking its own nervous system in patients with multiple sclerosis (MS) appears safe in trials.

The sheath around nerves cells, made of myelin, is destroyed in MS, leaving the nerves struggling to pass on messages.

A study on nine patients, reported in Science Translational Medicine, tried to train the immune system to cease its assault on myelin.

The MS Society said the idea had "exciting potential".

As nerves lose their ability to talk to each other, the disease results in problems moving and balancing and can affect vision.

There are drugs that can reduce number and severity of attacks, but there is no cure.

Retraining

The disease is caused by the body's immune system thinking that myelin is a foreign body like a flu virus.

Researchers at the Northwestern University Feinberg School of Medicine developed a technique to retrain the immune system.

They took blood samples and coupled white blood cells, a part of the immune system, to fragments of myelin. This was injected back into the patients to make them tolerate myelin.

The researchers said the therapy appeared safe. The study was too small to prove whether it benefited patients, but the researchers did report a calming of the immune reaction.

Prof Stephen Miller said: "Our approach leaves the function of the normal immune system intact. That's the holy grail."

He said future trials would target patients in the early stages.

He said: "We want to treat patients as early as possible in the disease before they have paralysis due to myelin damage, once the myelin is destroyed, it's hard to repair that."

Dr Susan Kohlhaas, head of biomedical research at the MS Society, said: "Being able to specifically stop the immune system attacking myelin but still keeping it fully functional poses an exciting potential therapy for people with MS.

"We were interested to see this novel way of re-programming the immune system shown to be well tolerated in this very small study.

"More research is now needed and we eagerly await the results of any future larger clinical trials of this therapy."

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Health stories

RSS

Features & Analysis

  • Stained glass of man with swordFrance 1 England 0

    The most important battle you have probably never heard of


  • Golden retriever10 things

    Dogs get jealous, and nine more nuggets from the week's news


  • Pro-Israel demonstrators shout slogans while protesting in Berlin - 25 July 2014Holocaust guilt

    Gaza conflict leaves Germans confused over who to support


  • The emir of Kuwait Sheikh Sabah al-Ahmad al-Jaber al-SabahFreedoms fear

    Growing concern for rights as Kuwait revokes citizenships


BBC Future

(SPL)

How to learn while you sleep

Enhance memory with your eyes shut Read more...

Programmes

  • Leader of Hamas Khaled MeshaalHARDtalk Watch

    BBC exclusive: Hamas leader on the eagerness to end bloodshed in Gaza

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.